On CNBC’s “Mad Money Lightning Round,” Jim Cramer recommended to hold Texas Instruments Incorporated (NASDAQ:TXN).
Supporting his view, Truist Securities analyst William Stein, on Dec. 19, maintained a Hold rating on Texas Instruments and raised the price target from $175 to $195.
Crane Company (NYSE:CR) is a “good” company, Cramer said.
According to recent news, Crane, on Jan. 5, announced it has closed the previously announced acquisition of Precision Sensors & Instrumentation from Baker Hughes (NASDAQ:BKR).
Cramer said he likes Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). “It actually has, by the way, real earnings, and it’s a very inexpensive stock. I think you’ve got a winner,” he added.
On the earnings front, Catalyst Pharmaceuticals reported better-than-expected third-quarter financial results on Nov. 5 and raised its FY25 sales guidance above estimates. Catalyst Pharmaceuticals reported quarterly earnings of 68 cents per share, which beat the analyst consensus estimate of 33 cents per share. The company reported quarterly sales of $148.392 millio,n which beat the analyst consensus estimate of $136.802 million.
Price Action:
- Texas Instruments shares fell 0.3% to settle at $188.53 on Tuesday.
- Crane shares gained 0.9% to settle at $204.73 on Tuesday.
- Catalyst Pharmaceuticals shares fell 3.8% to close at $22.35.
Photo: Shutterstock
Recent Comments